Sulbactam

Indications
Intravenous
Gynaecological infections
Adult: 1.5 g (1 g ampicillin/0.5 g sulbactam) -3 g (2 g ampicillin/1 g sulbactam) every 6 hr. Max: 4 g sulbactam/day.
Child: ≥1 yr: 300 mg/kg daily (200 mg ampicillin/100 mg sulbactam), given via IV infusion in equally divided doses every 6 hr. ≥40 kg: 1.5 g (1 g ampicillin/0.5 g sulbactam) -3 g (2 g ampicillin/1 g sulbactam) IM/IV every 6 hr. Max treatment duration: 14 days.
Renal impairment: Dose reduction is required.
Intravenous
Intra-abdominal infections
Adult: 1.5 g (1 g ampicillin/0.5 g sulbactam) -3 g (2 g ampicillin/1 g sulbactam) every 6 hr. Max: 4 g sulbactam/day.
Child: ≥1 yr: 300 mg/kg daily (200 mg ampicillin/100 mg sulbactam), given via IV infusion in equally divided doses every 6 hr. ≥40 kg: 1.5 g (1 g ampicillin/0.5 g sulbactam) -3 g (2 g ampicillin/1 g sulbactam) IM/IV every 6 hr. Max treatment duration: 14 days.
Renal impairment: Dose reduction is required.
Intravenous
Skin and skin structure infections
Adult: 1.5 g (1 g ampicillin/0.5 g sulbactam) -3 g (2 g ampicillin/1 g sulbactam) every 6 hr. Max: 4 g sulbactam/day.
Child: ≥1 yr: 300 mg/kg daily (200 mg ampicillin/100 mg sulbactam), given via IV infusion in equally divided doses every 6 hr. ≥40 kg: 1.5 g (1 g ampicillin/0.5 g sulbactam) -3 g (2 g ampicillin/1 g sulbactam) IM/IV every 6 hr. Max treatment duration: 14 days.
Renal impairment: Dose reduction is required.
Intravenous
Acute pelvic inflammatory disease
Adult: 3 g (2 g ampicillin/1 g sulbactam) every 6 hr with doxycycline. Discontinue IV therapy 24 hr after clinical improvement; continue with oral doxycycline (100 mg bid) for 14 days to complete treatment.
Renal impairment: Dose reduction is required.

Special Populations: Dose and/or frequency of drug may need to be modified in renal impairment, but the ratio of ampicillin to sulbactam should still be kept at 2:1.
Contraindications
Hypersensitivity.
Warnings / Precautions
Hepatic disease, biliary obstruction, ingestion of alcohol, pregnancy and lactation.
Adverse Reactions
GI disturbances; hypersensitivity.
Potentially Fatal: Stevens-Johnson syndrome.
Drug Interactions
Probenecid may increase the serum concentrations of sulbactam.
See Below for More sulbactam Drug Interactions
Mechanism of Actions
Sulbactam, a penicillanic acid sulfone with β-lactamase inhibitory properties has weak antibacterial activity, but is an irreversible inhibitor of many plasmid-mediated and some chromosomal β-lactamases. It has a similar spectrum of β-lactamase inhibition to clavulanic acid, although it is less potent. It enhances the activity of penicillins and cephalosporins. It is usually given with ampicillin to increase the antimicrobial spectrum; may also be used with cefoperazone.
Absorption: Poorly absorbed from the GI tract.
Distribution: Distributed into breast milk. Protein binding: 38%.
Excretion: Half-life elimination: 1-1.3 hr. About 75-85% is excreted unchanged in the urine within 8 hr.
Storage Conditions
Intravenous: Sterile powder for inj: Store below 20°C.
ATC Classification
J01CG01 - sulbactam ; Belongs to the class of beta-lactamase inhibitors. Used in the systemic treatment of infections.
Storage
Intravenous: Sterile powder for inj: Store below 20°C.
Available As
  • Sulbactam 0.5 gm
  • Sulbactam 1 mg
  • Sulbactam Sodium 1000 mg
  • Sulbactam 1000 mg
  • Sulbactam 125 mg
  • Sterile Sulbactam 125 mg
  • Sulbactam Sodium 125 mg
  • Sulbactam 147 mg
  • Sulbactam 150 mg
  • Sulbactam 2 mg
  • Sulbactam Sodium 250 mg
  • Sulbactam 250 mg
  • Sulbactam Sodium 500 mg
  • Sterile Sulbactam 500 mg
  • Sulbactam 500 mg
  • Sulbactam 62.5 mg
  • Sulbactam 750 mg
  • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Sulbactam


    Sulbactam Containing Brands

    We are Developing Our database, More results coming soon.

    Sulbactam is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Sulbactam

    We are Developing Our database, More results coming soon.